{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:14:45Z","timestamp":1769192085417,"version":"3.49.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The objective of this meta-analysis was to compare the efficacy and safety between glucocorticoids combined with mycophenolate mofetil (MMF) versus glucocorticoids combined with cyclophosphamide (CTX) for henoch schonlein purpura nephritis (HSPN) in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Databases including PubMed, EMbase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang database were searched from the inception to April 5th, 2024. Eligible studies comparing glucocorticoids combined with MMF versus glucocorticoids combined with CTX for HSPN in children were included. Data were analyzed using Review Manager Version 5.3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Ten studies were included in the meta-analysis. Six randomized controlled trials (RCTs) and 4 non-randomized studies involving 675 patients were identified. Compared with CTX therapeutic schedule, MMF therapeutic schedule had a higher complete remission (CR) within the 6 months (OR 1.61, 95%CI 1.16\u20132.22, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.004) and CR within the 12 months (OR 1.73, 95%CI 1.00\u20132.97, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.05). However, there was no significant difference between MMF and CTX therapeutic schedule concerning total remission (TR) within the 6 months (OR 1.54, 95%CI 0.82\u20132.92, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.18) and TR within the 12 months (OR 2.08, 95%CI 0.86\u20135.01, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.10). In addition, incidences of gastrointestinal discomfort (OR 0.33, 95%CI 0.19\u20130.56, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.0001), liver function injury (OR 0.28, 95%CI 0.09\u20130.87, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03), myelosuppression (OR 0.15, 95%CI 0.06\u20130.41, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.0001), alopecia (OR 0.25, 95%CI 0.07\u20130.91, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.03) in MMF therapeutic schedule were all lower than CTX therapeutic schedule. There was no statistically significant difference between the 2 therapeutic schedules concerning infection (OR 0.90, 95%CI 0.50\u20131.61, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.72), rash (OR 0.38, 95%CI 0.07\u20132.04, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.26).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Glucocorticoids combined with MMF had a higher CR and lower incidence of adverse effects compared with glucocorticoids combined with CTX in the treatment of HSPN in children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039059","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:13:37Z","timestamp":1722003217000},"page":"e39059","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of mycophenolate mofetil versus cyclophosphamide therapy for Henoch schonlein purpura nephritis in children: A meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"Di","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Affiliated Changzhou NO.2 People\u2019s Hospital of Nanjing Medical University, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Affiliated Changzhou NO.2 People\u2019s Hospital of Nanjing Medical University, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingkui","family":"Lu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, People\u2019s Hospital of Hainan Tibetan Autonomous Prefecture, Hainan Tibetan Autonomous Prefecture, Qinghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, People\u2019s Hospital of Hainan Tibetan Autonomous Prefecture, Hainan Tibetan Autonomous Prefecture, Qinghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7783-2709","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China"},{"name":"Department of Nephrology, Wujin Hospital Affiliated with Jiangsu University, Changzhou, Jiangsu, China"},{"name":"Department of Nephrology, People\u2019s Hospital of Hainan Tibetan Autonomous Prefecture, Hainan Tibetan Autonomous Prefecture, Qinghai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/18756336MTA2lNDYc2","article-title":"Henoch-Sch\u00f6nlein purpura in children: an updated review.","volume":"16","author":"Leung","year":"2020","journal-title":"Curr Pediatr Rev"},{"key":"R2-20250716","doi-asserted-by":"crossref","first-page":"e0270796","DOI":"10.1371\/journal.pone.0270796","article-title":"Epidemiology of biopsy-proven Henoch-Sch\u00f6nlein purpura nephritis in children: a nationwide survey in Japan.","volume":"17","author":"Terano","year":"2022","journal-title":"PLoS One"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s11255-021-03063-7","article-title":"Comparison of clinical, pathological and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis and IgA nephropathy.","volume":"54","author":"Torun Bayram","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"R4-20250716","doi-asserted-by":"crossref","first-page":"956397","DOI":"10.3389\/fphar.2022.956397","article-title":"Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis.","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R5-20250716","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00467-018-4134-9","article-title":"Correlation between endocapillary proliferative and nephrotic-range proteinuria in children with Henoch-Sch\u00f6nlein purpura nephritis.","volume":"34","author":"Yang","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R6-20250716","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/PHMT.S379862","article-title":"Diagnostic and management strategies of IgA vasculitis Nephritis\/Henoch-Sch\u00f6nlein purpura nephritis in pediatric patients: current perspectives.","volume":"14","author":"Sestan","year":"2023","journal-title":"Pediatric Health Med Ther"},{"key":"R7-20250716","first-page":"647","article-title":"Evidence-based guidelines for the diagnosis and treatment of pediatric Henoch-Sch\u00f6nlein purpura nephritis.","volume":"55","year":"2017","journal-title":"Chin J Pediatr"},{"key":"R8-20250716","doi-asserted-by":"crossref","first-page":"946165","DOI":"10.3389\/fphar.2022.946165","article-title":"Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: a retrospective cohort study.","volume":"13","author":"Jia","year":"2022","journal-title":"Front Pharmacol"},{"key":"R9-20250716","first-page":"665","article-title":"Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: a network meta-analysis.","volume":"19","author":"Zhou","year":"2020","journal-title":"Exp Ther Med"},{"key":"R10-20250716","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00467-011-2057-9","article-title":"Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil.","volume":"27","author":"Du","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R11-20250716","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00467-017-3846-6","article-title":"Mycophenolate mofetil following glucocorticoid treatment in Henoch-Sch\u00f6nlein purpura nephritis: the role of early initiation and therapeutic drug monitoring.","volume":"33","author":"Hackl","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"R12-20250716","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R13-20250716","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2288-7-10","article-title":"Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.","volume":"7","author":"Shea","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"R14-20250716","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/BRS.0000000000001061","article-title":"2015 Updated method guideline for systematic reviews in the Cochrane back and neck group.","volume":"40","author":"Furlan","year":"2015","journal-title":"Spine"},{"key":"R15-20250716","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R16-20250716","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40272-022-00506-1","article-title":"Efficacy and safety of tacrolimus in the treatment of pediatric Henoch-Sch\u00f6nlein purpura nephritis.","volume":"24","author":"Wu","year":"2022","journal-title":"Paediatr Drugs"},{"key":"R17-20250716","first-page":"1113","article-title":"Therapeutic effect of mycophenolate mofetil or cyclophosphamide in children with Henoch-Sch\u00f6nlein purpura nephritis of different age groups.","volume":"25","author":"DU","year":"2023","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"R18-20250716","first-page":"338","article-title":"Efficacy and safety of mycophenolate mofetil versus cyclophosphamide in the treatment of Henoch-Sch\u00f6nlein purpura nephritis with nephrotic-range proteinuria in children: a prospective randomized controlled trial.","volume":"23","author":"Geng","year":"2021","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"R19-20250716","first-page":"41","article-title":"Effects of Mycophenolate mofetil combined with Glucocorticoid on renal function and immune function in children with henoch-schonlein purpura nephritis.","volume":"7","author":"Yin","year":"2023","journal-title":"Modern Med Health Res"},{"key":"R20-20250716","first-page":"877","article-title":"Study on the effect of mycophenolate mofetil in the treatment of children with Henoch-Schonlein purpura nephritis.","volume":"19","author":"Qiao","year":"2018","journal-title":"Chin Prev Med"},{"key":"R21-20250716","first-page":"1140","article-title":"Clinical research of mycophenolate mofetil and cyclophosphamide in the treatment of children Henoch-Schonlein purpura nephritis accompanied by nephrofic syndrome.","volume":"50","author":"Miao","year":"2015","journal-title":"Jiangxi Med J"},{"key":"R22-20250716","first-page":"352","article-title":"Treatment of children Henoch-Schonlein purpura nephritis with mycophenolate mofetil and cyclophosphamide.","volume":"39","author":"Du","year":"2010","journal-title":"J China Med Univ"},{"key":"R23-20250716","first-page":"1041","article-title":"Effects of CTX and MMF on the levels of \u03b3\u03b4T cells and related factors in PBMCs of children with allergic purpura nephritis with proteinuria.","volume":"54","author":"Tian","year":"2022","journal-title":"Inner Mongolia Med"},{"key":"R24-20250716","first-page":"95","article-title":"To compare the clinical efficacy of intravenous injection of MMF and cyclophosphamide in the treatment of henoch schonlein purpura nephritis.","volume":"30","author":"Wu","year":"2017","journal-title":"Med Inform"},{"key":"R25-20250716","first-page":"271","article-title":"Comparing the effects of mycophenolate mofetil and cyclophosphamide in the treatment of children Henoch-Schonlein purpura nephritis accompanied by nephrofic syndrome.","volume":"25","author":"Yu","year":"2007","journal-title":"J Chin Pediatr"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12906-021-03415-x","article-title":"Chinese patent herbal medicine Huaiqihuang for Henoch-Schonlein purpura nephritis in children: a systematic review of randomized controlled trials.","volume":"21","author":"Xue","year":"2021","journal-title":"BMC Complement Med Ther"},{"key":"R27-20250716","first-page":"229","article-title":"Henoch-Sch\u00f6nlein Purpura (IgA Vasculitis): rapid evidence review.","volume":"102","author":"Reamy","year":"2020","journal-title":"Am Fam Physician"},{"key":"R28-20250716","doi-asserted-by":"crossref","first-page":"e22328","DOI":"10.1097\/MD.0000000000022328","article-title":"Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis.","volume":"99","author":"Jiang","year":"2020","journal-title":"Medicine (Baltim)"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s10067-021-05794-5","article-title":"Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.","volume":"40","author":"Ma","year":"2021","journal-title":"Clin Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T23:01:47Z","timestamp":1752706907000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":29,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039059","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}